References
- Hall DG. Boronic acids. New York (NY): John Wiley and Sons; 2005
- Marinaro WA, Schieber LJ, Munson EJ, et al. Properties of a model aryl boronic acid and its boroxine. J Pharm Sci 2012;101:3190–8
- Adams J, Kauffman M. Development of the proteasome inhibitor velcade (bortezomib). Cancer Invest 2004;22:304–11
- Paramore A, Frantz S. Bortezomid. Nat Rev Drug Discov 2003;2:611–12
- Adams J, Behnke M, Chen S, et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acid. Bioorg Med Chem Lett 1998;8:333–8
- Vullo D, Ruusuvuori E, Kaila K, et al. Carbonic anhydrase inhibitors. Inhibition of the cytosolic human isozyme VII with anions. Bioorg Med Chem Lett 2006;16:3139–43
- De Simone G, Supuran CT. (In)organic anions as carbonic anhydrase inhibitors. J Inorg Biochem 2012;111:117–29
- Winum JY, Innocenti A, Scozzafava A, et al. Carbonic anhydrase inhibitors. Inhibition of the human cytosolic isoforms I and II and transmembrane, tumor-associated isoforms IX and XII with boronic acids. Bioorg Med Chem 2009;17:3649–52
- Galic B. Boroxine composition for removal of skin changes. United States Patent (2012) US 8 278 289
- Galic B. Removal of skin changes. European Patent (2013) EP 1 996 514
- Haveric S, Haveric A, Bajrovic K, et al. Effects of dipotassium-trioxohydroxytetrafluorotriborate (K2[B3O3F4OH]) on genetic material and inhibition of cell division in human cell cultures. Drug Chem Toxicol 2011;34:250–4
- Islamovic S, Galic B, Milos M. A study of the inhibition of catalase by dipotassium-trioxohydroxytetrafluorotriborate K2[B3O3F4OH. J Enzyme Inhib Med Chem. [Epub ahead of print]. doi: 10.3109/14756366.2013.848203
- Vullo D, Milos M, Galic B, et al. Dipotassium-trioxohydroxy tetrafluorotriborate, K2[B3O3F4OH], is a potent inhibitor of human carbonic anhydrases. J Enzyme Inhib Med Chem (accepted for publication)
- Dexter DL, Kowalski HM, Blazar BA, et al. Heterogeneity of tumor cells from a single mouse mammary tumor. Cancer Res 1978;38:3174–81
- Heppner GH, Dexter DL, DeNucci T, et al. Heterogeneity in drug sensitivity among tumor cell subpopulations of a single mammary tumor. Cancer Res 1978;38:3758–63
- Heppner GH, Miller FR, Shekhar PM. Nontransgenic models of breast cancer. Breast Cancer Res 2000;2:331–4
- Morecki S, Yacovlev L, Slavin S. Effect of indomethacin on tumorigenicity and immunity induction in a murine model of mammary carcinoma. Int J Cancer 1998;75:894–9
- Pulaski BA, Clements VK, Pipeling MR, Ostrand-Rosenberg S. Immunotherapy with vaccines combining MHC class II/CD80+tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon gamma. Cancer Immunol Immunother 2000;49:34–45
- Fidler IJ. Metastasis: quantitative analysis of distribution and fate of tumor emboli labeled with 125I-5-Iodo-2-deoxyuridine. J Nat Cancer Inst 1970;45:773–82
- Ryss IG, Slutskaya MM. Report on the platinum sector. Akad Nauk SSSR 1951;26:216–18
- Finney DJ. Probit analysis. Cambridge, England: Cambridge University Press; 1952
- Kim V. Probit analysis. Available from: http://userwww.sfsu.edu/efc/classes/biol710/probit/ProbitAnalysis.pdf [last accessed 24 Apr 2014]
- Martin DS, Stolfi RL, Sawyer RC, et al. High-dose 5-fluorouracil with delayed uridine “rescue” in mice. Cancer Res 1982;42:3964–70
- Stolfi RL, Martin DS, Sawyer RC, Spiegelman S. Modulation of 5-Fluorouracil-induced toxicity in mice with interferon or with the intreferon inducer polyinosinic-polycytidylic acid. Cancer Res 1983;43:561–6